How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies

Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):95-97. doi: 10.1080/17474124.2017.1266935. Epub 2016 Dec 11.

Authors

Rachel W Winter¹, Robert Burakoff¹

Affiliation

¹ a Division of Gastroenterology, Hepatology and Endoscopy , Brigham and Women's Hospital , Boston , MA , USA.

PMID: 27900879
DOI: 10.1080/17474124.2017.1266935

No abstract available

Keywords: Crohn’s disease; biologics; inflammatory bowel disease; therapeutics; treatment.

Publication types

Editorial
Review

MeSH terms

Anti-Inflammatory Agents / adverse effects
Anti-Inflammatory Agents / therapeutic use*
Biological Products / adverse effects
Biological Products / therapeutic use*
Crohn Disease / diagnosis
Crohn Disease / drug therapy*
Drug Therapy, Combination
Gastrointestinal Agents / adverse effects
Gastrointestinal Agents / therapeutic use*
Humans
Patient Selection
Severity of Illness Index
Treatment Outcome

Substances

Anti-Inflammatory Agents
Biological Products
Gastrointestinal Agents